$42.18
15.59% yesterday
Nasdaq, Nov 15, 10:00 pm CET
ISIN
US05370A1088
Symbol
RNA
Sector
Industry

Avidity Biosciences Inc Stock price

$42.18
-4.52 9.68% 1M
+12.67 42.93% 6M
+33.13 366.08% YTD
+35.95 577.05% 1Y
+17.49 70.84% 3Y
+13.68 48.00% 5Y
+13.68 48.00% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-7.79 15.59%
ISIN
US05370A1088
Symbol
RNA
Sector
Industry

Key metrics

Market capitalization $5.03b
Enterprise Value $3.45b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 341.05
P/S ratio (TTM) P/S ratio 497.28
P/B ratio (TTM) P/B ratio 3.34
Revenue growth (TTM) Revenue growth -0.19%
Revenue (TTM) Revenue $10.12m
EBIT (operating result TTM) EBIT $-324.69m
Free Cash Flow (TTM) Free Cash Flow $-188.51m
Cash position $1.59b
EPS (TTM) EPS $-2.90
P/E forward negative
P/S forward 560.72
EV/Sales forward 412.03
Short interest 15.15%
Show more

Is Avidity Biosciences Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Avidity Biosciences Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Avidity Biosciences Inc forecast:

11x Buy
100%

Analyst Opinions

11 Analysts have issued a Avidity Biosciences Inc forecast:

Buy
100%

Financial data from Avidity Biosciences Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
10 10
0% 0%
100%
- Direct Costs 2.65 2.65
34% 34%
26%
7.46 7.46
22% 22%
74%
- Selling and Administrative Expenses 69 69
70% 70%
679%
- Research and Development Expense 261 261
42% 42%
2,577%
-322 -322
48% 48%
-3,182%
- Depreciation and Amortization 2.65 2.65
34% 34%
26%
EBIT (Operating Income) EBIT -325 -325
46% 46%
-3,208%
Net Profit -280 -280
39% 39%
-2,772%

In millions USD.

Don't miss a Thing! We will send you all news about Avidity Biosciences Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Avidity Biosciences Inc Stock News

Positive
Investors Business Daily
2 days ago
Shares of Avidity Biosciences surged to a record high Wednesday after the company showed its hand in the cardiovascular space. The post Avidity Bio Has Surged 416% This Year — And That's Before Today's 'Game-Changing' News appeared first on Investor's Business Daily.
Neutral
PRNewsWire
4 days ago
Avidity expands  its leading RNA delivery technology into precision cardiology with two new wholly-owned development candidates targeting rare genetic cardiomyopathies: AOC 1086 to treat PLN Cardiomyopathy and AOC 1072 to treat PRKAG2 Syndrome AOC 1072 and AOC 1086 preclinical data demonstrated robust siRNA delivery to the heart and targeted knockdown with potent reduction of approximately 80% ...
Neutral
PRNewsWire
8 days ago
Enrollment in global Phase 3 HARBOR™ study for del-desiran in DM1 is on track Avidity initiated biomarker cohort for del-brax FORTITUDE™ study for FSHD; pursuing a potential accelerated approval path for del-brax Reported positive del-zota data from Phase 1/2 EXPLORE44™ trial for DMD44 Avidity to provide a first look at precision cardiology candidates and a glimpse at next-generation technology...
More Avidity Biosciences Inc News

Company Profile

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) designed to treat a range of serious diseases. The company's lead product candidate is AOC 1001 for treatment of myotonic dystrophy type 1; and four other muscle programs, which focus on the treatment of muscle atrophy, duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe disease. It utilizes its proprietary AOC platform to design, engineer, and develop therapeutics that combine tissue selectivity of monoclonal antibodies and precision of oligonucleotide therapies to access previously undruggable tissue and cell types, and target underlying genetic drivers of diseases. The company also has development programs that focuses on immune and other cell types. Avidity Biosciences, Inc. was founded in 2012 and is based in La Jolla, California.

Head office United States
CEO Sarah Boyce
Employees 253
Founded 2012
Website www.aviditybiosciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today